London. 12 January 2015, 09.00 AM GMT. Norgine Ventures today announced that it has successfully exited its investment in Internis Pharmaceuticals Limited following the acquisition of Internis by an undisclosed pharmaceutical company in December 2014. This transaction represents a significant achievement for this exciting and innovative British company.
Internis, founded in 2010 by Charles Tannenbaum, Martin Knight and Alan Walker, launched the first fully licensed prescription vitamin D3 oral product to the UK’s health service in 2012, Fultium D3. Norgine Ventures’ backing of Internis over the past couple of years enabled the company to accelerate its commercial development and accelerate its new product development programme.
Since launch, this product has enjoyed widespread success and has maintained its brand leadership in this new market. Internis experienced rapid and significant growth over the last twenty-four months.
Ex- Joint Internis CEO Charles Tannenbaum, stated:
“We are delighted to have had Norgine Ventures as a partner throughout our development from our early days until exit. Their investment, support and belief in our company and products has enabled us to achieve our growth potential and realise significant value creation in a short period of time.”
Notes to Editors:
For further information please contact:
Julien Michaux, Norgine Ventures, +44 1895826600, firstname.lastname@example.org
Caroline Ashe, Norgine Corporate Communications: Tel: +44 1895 826218, CAshe@norgine.com
Norgine is a European specialist pharmaceutical company that has been operating for over 100 years. The company employs over 1,000 people and has a strong presence in all key European markets. Total revenue in 2013 was €274 million.
Norgine’s expertise and ‘know how’ in Europe allows them to develop, manufacture and commercialise products that offer real value to healthcare professionals, payers and patients across Europe. The company’s unique approach and infrastructure allows it to focus on developing strong partner opportunities for growth in Europe.
Norgine is headquartered in the Netherlands with global operations in Amsterdam and in Harefield, UK. Norgine’s R&D site is in Hengoed, Wales and its two manufacturing sites are in Hengoed, Wales and in Dreux, France.
For more information, please visit www.norgine.com
About Norgine Ventures
Norgine Ventures was started in 2012 to diversify Norgine’s activities and to foster innovation in the healthcare sector. Norgine Ventures provides debt and debt-like financing to innovative, fast growing companies in the fields of healthcare and life sciences, in Europe and the US.
For more information: www.norgineventures.com
NORGINE and the sail logo are trademarks of the Norgine group of companies.